Ampersand Biomedicines is a multi-product platform that develops programmable medicines that target disease sites precisely.
Ampersand Biomedicines has raised $65.0M in total funding. The most recent round was Series B. The last funding was announced in March 2025.
Ampersand Biomedicines's investors include Eli Lilly, Flagship Pioneering.
Ampersand Biomedicines is headquartered in Boston, United States.
Ampersand Biomedicines is a multi-product platform that develops programmable medicines that target disease sites precisely.
Ampersand Biomedicines is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ampersand Biomedicines — Funding & Investors." VCBacked, March 19, 2025, https://www.vcbacked.co/company/ampersand-biomedicines. Accessed October 27, 2026.
VCBacked. (2025). Ampersand Biomedicines — Funding & Investors. Retrieved October 27, 2026, from https://www.vcbacked.co/company/ampersand-biomedicines
{{cite web |title=Ampersand Biomedicines — Funding & Investors |url=https://www.vcbacked.co/company/ampersand-biomedicines |website=VCBacked |access-date=October 27, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated